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a b s t r a c t
HERG (human ether-a`-go-go-related gene) encodes channels responsible for the cardiac
rapid delayed rectifier potassium current, IKr. This study investigated the effects on HERG
channels of doxepin, a tricyclic antidepressant linked to QT interval prolongation and
cardiac arrhythmia. Whole-cell patch-clamp recordings were made at 37 8C of recombinant
HERG channel current (IHERG), and of native IKr ‘tails’ from rabbit ventricular myocytes.
Doxepin inhibited IHERG with an IC50 value of 6.5  1.4 mM and native IKr with an IC50 of
4.4  0.6 mM. The inhibitory effect on IHERG developed rapidly upon membrane depolariza-
tion, but with no significant dependence on voltage and with little alteration to the voltage-
dependent kinetics of IHERG. Neither the S631A nor N588K inactivation-attenuating muta-
tions (of residues located in the channel pore and external S5-Pore linker, respectively)
significantly reduced the potency of inhibition. The S6 point mutation Y652A increased the
IC50 for IHERG blockade by 4.2-fold; the F656A mutant also attenuated doxepin’s action at
some concentrations. HERG channel blockade is likely to underpin reported cases of QT
interval prolongation with doxepin. Notably, this study also establishes doxepin as an
effective inhibitor of mutant (N588K) HERG channels responsible for variant 1 of the short QT
syndrome.
# 2007 Elsevier Inc.
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Open access under CC BY-NC-ND license.1. Introduction
Diverse cardiac and non-cardiac drugs are associated with
prolongation of the rate-corrected QT (QTc) interval of the
electrocardiogram and with a risk of the potentially fatal
arrhythmia Torsade de Pointes (TdP) [1–4]. The majority of such
agents exert a common action of inhibiting the cardiac rapidly
activating delayed rectifier K+ current (IKr). IKr is a major
determinant of ventricular action potential repolarization
and, thereby, of the QTc interval [2,4,5]. The pore-forming
subunit of IKr channels is encoded by HERG (human ether-a`-* Corresponding authors. Tel.: +117 928 9028; fax: +117 928 8923.
E-mail addresses: harry.witchel@bristol.ac.uk (H.J. Witchel), jules.h
0006-2952 # 2007 Elsevier Inc.
doi:10.1016/j.bcp.2007.04.024
Open access under CC BY-NC-ND license.go-go-related gene [6,7]). HERG channels appear to have a
larger pore cavity than other (Kv) six transmembrane domain
K+ channels and possess particular aromatic amino-acid
residues in the S6 region of the channel [5,8–10]. These
features combine to confer a high susceptibility to pharma-
cological blockade upon the HERG channel. Indeed, the
association between drug-induced QTc interval prolongation
and pharmacological blockade of HERG channels is suffi-
ciently strong that drug-screening against recombinant HERG
channels is now an important component of cardiac safety-
pharmacology during drug development [11–13].ancox@bristol.ac.uk (J.C. Hancox).
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related to amitriptyline and imipramine that combines
antidepressant and sedative actions [14]. Initially doxepin
was suggested to have better cardiac safety than other TCA
drugs [15]. However, a subsequent review of the clinical and
animal data [16] and a study in depressed patients [17] found
no evidence that doxepin had fewer cardiovascular effects
than other TCAs. Moreover, similar to other TCAs, doxepin can
be cardiotoxic in overdose [14]. Adverse cardiac effects
associated with doxepin include premature ventricular com-
plexes (PVCs) and wide QRS complexes on the electrocardio-
gram. Furthermore, there are a number of documented cases
of QT interval prolongation with doxepin [18–20]. For example,
in overdose doxepin has been associated with a greatly
prolonged QTc interval (reaching 580 ms) and TdP [19], whilst
QT interval prolongation and syncope have been reported for
doxepin in combination with methadone and b blocker use
[20]. At present there is no information on the basis for QTc
prolongation with doxepin. However, other TCAs including
imipramine and amitryptiline have been demonstrated to
inhibit recombinant HERG channels [21–23] and we hypothe-
sised that doxepin is also likely to act as an inhibitor of HERG
channel current (IHERG). The present study was conducted to
test this hypothesis and to characterise the nature of any
observed IHERG blockade.2. Methods
2.1. Maintenance of mammalian cell lines stably
expressing wild-type and mutant HERG channels
Experiments on wild-type HERG were performed on a cell line
(Human Embryonic Kidney; HEK 293) stably expressing HERG
(donated by Dr Craig January, University of Wisconsin [24]),
except for those in Fig. 8; these utilised a cell line stably
expressing lower levels of HERG developed in this laboratory,
for use with high external [K+] (for comparison with the F656A
mutant, see Section 2.2 below). Cell lines stably expressing
HERG and its mutants, F656A and Y652A were maintained as
described previously [25]. Cell lines stably expressing the
S631A [26] and N588K [27] mutants were made from appro-
priately mutated HERG sequences using previously described
methods [25]. Cells were passed using a non-enzymatic
dissociating agent (Splitase, AutogenBioclear) and plated out
onto small sterilised glass coverslips in 30 mm petri dishes
containing a modification of Dulbecco’s modified Eagle’s
medium with Glutamax-1 (DMEM; Gibco, Gibco/Invitrogen,
Paisley, UK), supplemented with 10% fetal bovine serum
(Gibco), 400 mg ml1 gentamycin (Gibco) and 400 mg ml1
geneticin (G418; Gibco). Treatment of the mutant cell lines
was identical to treatment of the wild-type cell line except that
cultures were maintained with 800 mg ml1 of hygromycin.
The cells were incubated at 37 8C for a minimum of two days
prior to any electrophysiological study.
2.2. Experimental solutions
Whole-cell patch-clamp measurements of wild-type (WT)
and mutant IHERG were made at 37  1 8C. Once in theexperimental chamber cells were superfused with a
standard extracellular Tyrode’s solution containing (in
mM): 140 NaCl, 4 KCl, 2.5 CaCl2, 1 MgCl2, 10 glucose, 5 HEPES,
(titrated to pH 7.45 with NaOH). Similar to other studies from
our laboratory (e.g. [28,29]), for experiments employing the S6
mutant F656A (which shows comparatively low levels of
channel expression [8,25]) and its WT control, the external
solution contained 94 mM KCl (the NaCl concentration was
correspondingly reduced). Experimental solutions were
applied using a home-built, warmed, solution delivery
system that exchanged the solution surrounding a cell in
<1 s. Doxepin powder (Sequoia Research Products and Sigma-
Aldrich) was dissolved in Tyrode’s solution to produce initial
stock solutions of either 10 or 50 mM, which were serially
diluted to produce working solutions ranging from 0.1 mM
to 1 mM.
The pipette dialysis solution for IHERG measurement
contained (in mM): 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, 10
HEPES (titrated to pH 7.2 with KOH) [28,29]. Patch-pipettes
were heat-polished to 2.5–4 MV. No correction was made for
the ‘pipette-to-bath’ liquid junction potential, which was
measured to be 3.2 mV.
2.3. Experiments on rabbit isolated ventricular myocytes
One series of experiments was performed to investigate
blockade by doxepin of native IKr from adult ventricular
myocytes (Results, Fig. 2). For these, male New Zealand
white rabbits (2–3 kg) were killed humanely in accordance
with UK Home Office legislation. Ventricular myocytes
were then isolated by a combination of mechanical and
enzymatic dispersion, using previously described methods
[30,31]. Pipette and external solutions for IKr measurement
were identical to those described above for IHERG measure-
ment.
2.4. Electrophysiological recording and analysis
Whole-cell patch-clamp recordings were made using
Axopatch 200 or 200B amplifiers (Axon Instruments) and a
CV201 head-stage. Between 75 and 80% of the pipette
series resistance was compensated. Voltage-clamp com-
mands were generated using ‘WinWCP’ (John Dempster,
Strathclyde University), Clampex 8 (Axon Instruments), or
‘Pulse’ software (HEKA Electronik). Data were recorded either
via a Digidata 1200B interface (Axon Instruments) or an
Instrutech VR-10B interface and stored on the hard-disk of a
personal computer. The voltage-protocols employed for
specific experiments are described either in the relevant
‘results’ text, or are shown diagrammatically on the relevant
figures; unless otherwise stated in the text, the holding
membrane potential between experimental sweeps was
80 mV. Data are presented as mean  S.E.M. Statistical
comparisons were made using, as appropriate, paired and
unpaired t-tests or one-way analysis of variance (Anova)
(Prism 3 or Instat, Graphpad Inc.). P values of less than 0.05
were taken as significant; ns = no statistically significant
difference.
The following equations were used for numerical analysis
and graphical fits to data:
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doxepin was determined using the equation:
Fractional block ¼ 1 IHERGDOXEPIN
IHERGCONTROL
 
(1)
where ‘Fractional block’ refers to the degree of inhibition of
IHERG by a given concentration of doxepin; IHERG–DOXEPIN and
IHERG–CONTROL represent current amplitudes in the presence
and absence of doxepin.
Concentration–response data were fitted by a standard Hill
equation of the form:
Fractional block ¼ 1
1þ ðIC50=DOXEPINÞh
(2)
where IC50 is [DOXEPIN] producing half-maximal inhibition of
the IHERG tail and h is the Hill coefficient for the fit.
Half-maximal voltage values for IHERG activation were
obtained by fitting IHERG tail-voltage (I–V) relations with a
Boltzmann distribution equation of the form:
I ¼ Imax
1þ exp V0:5Vmk
   (3)
where I is the IHERG tail amplitude following test potential Vm,
Imax the maximal IHERG tail observed during the protocol, V0.5
the potential at which IHERG was maximally activated, and k is
the slope factor describing IHERG activation. Data from each
individual experiment were fitted by this equation to derive
V0.5 and k values in ‘control’ and with doxepin. The resultant
mean V0.5 and k values obtained from pooling values from
each experiment were then used to calculate the mean activa-
tion relations plotted in Fig. 3.
Parameters describing voltage-dependent inactivation of
IHERG were derived from fits to voltage-dependent availability
plots with the equation:
Inactivation parameter ¼ 1 1
1þ exp ðV0:5  VmÞ=kð Þð Þ
 
(4)
where ‘inactivation parameter’ at any test potential, Vm,
occurs within the range 1–0, V0.5 is the voltage at which IHERG
was half-maximally inactivated and k describes the slope
factor for the relationship.3. Results
3.1. Doxepin produces concentration-dependent inhibition
of WT IHERG
IHERG was elicited by the protocol shown in the inset of Fig. 1A,
which is a standard protocol used to study IHERG pharmacology
in this laboratory (e.g. [28,29,32]). Membrane potential was
stepped from 80 to +20 mV for 2 s followed by a 4-s step to
40 mV to elicit IHERG tails. A brief (50 ms) pulse to 40 mV
preceded the step to +20 mV in order to monitor the
instantaneous current without activation of IHERG (peak
outward IHERG tails on repolarization to –40 mV were comparedwith the instantaneous current during the 50 ms pulse to
40 mV, in order to measure IHERG tail amplitude). This voltage
protocol was applied repeatedly (at 20 s intervals) prior to and
during the application of doxepin. Fig. 1A shows a represen-
tative recording of IHERG in control, 5 min after the addition of
10 mM doxepin and 5 min following wash-out of the drug.
Doxepin produced a substantial inhibition of IHERG; this was
largely reversible upon washout (to 73  9% of control in six
cells to which 10 mM doxepin was applied). Fig. 1B shows
records for the same cell before and at increasing times during
doxepin exposure, indicating that blockade was maximal
within 4–5 min of drug application. Fig. 1C shows a plot of
mean  S.E.M. fractional block of IHERG tails by four different
concentrations of doxepin, fitted by Eq. (2). The IC50 for
doxepin inhibition of IHERG with this protocol was 6.5  1.4 mM
and the Hill coefficient for the fit was 1.0  0.2. IHERG blockade
by doxepin was not accompanied by statistically significant
changes to the time-course of deactivation of the time-
dependent component of IHERG tails on repolarization to
40 mV: bi-exponential fitting of the time-dependent tail
current decline yielded fast time-constants of deactivation
(tfast) of 203  15 and 273  21 ms in control solution and 10 mM
doxepin, respectively (n = 6; p > 0.05, paired t-test), and slow
time-constants of deactivation (tslow) of 1164  141 and
1499  131 ms (p > 0.1). Doxepin did not influence signifi-
cantly the relative proportions of deactivating current
described by the fast and slow time-constants of deactivation
(the proportion of deactivating current fitted by the tfast was
0.6 in both control and doxepin).
It has been suggested that pharmacological inhibition of
IHERG by some drugs may vary between different stimulus
protocols [33]. Therefore, we also investigated IHERG blockade
by doxepin using an action potential (AP) voltage waveform
[32,34]. The voltage-command used (shown in the lower panel
of Fig. 2A) was a previously acquired, digitised AP from a rabbit
ventricular myocyte. This was applied repeatedly (at 4 s
intervals) from a holding potential of 80 mV [32]. The upper
panel of Fig. 2A shows traces in the absence and presence of
doxepin. Peak outward IHERG during the repolarizing phase of
the AP was inhibited 60  12% (n = 5) by 10 mM doxepin, which
does not differ significantly from the extent of IHERG tail
current blockade by this concentration obtained using the
protocol shown in Fig. 1 (62  4%; n = 6; p > 0.8; unpaired t-
test).
In order to determine effects of doxepin on native IKr, three
drug concentrations (1, 10 and 100 mM) were applied to
ventricular myocytes under whole-cell patch clamp. The
command protocol for these experiments (similar to [32]) is
shown in Fig. 2B and IKr tails were monitored on repolarization
from +20 to 40 mV. Under our conditions, the outward tail
currents observed on repolarization to 40 mV were almost
completely abolished by 1 mM dofetilide (91  3% blockade;
n = 7), verifying that these were carried by IKr with little or no
contamination from overlapping currents. Fig. 2C shows
representative IKr tails on repolarization from +20 to
40 mV in the absence and presence of 100 mM doxepin; at
this concentration the current was largely abolished. Fig. 2D
contains mean  S.E.M fractional block data for the tested
doxepin concentrations, fitted by Eq. (2). The derived IC50 for
doxepin inhibition of native IKr tails was 4.4  0.6 mM, in good
Fig. 1 – Concentration dependent inhibition of IHERG by doxepin. (A) Representative currents in the absence, presence (5 min)
and following wash off (5 min) of 10 mM doxepin, elicited by the voltage protocol shown in the inset. (B) Representative
currents (upper traces; lower trace shows voltage protocol), from the same cell as in A, in the absence and during doxepin
exposure. ‘Control’ refers to current prior to doxepin exposure, whilst numbered time-points indicate currents sampled at
1–5 min of doxepin application. (C) Mean fractional block produced by four different concentrations of doxepin fitted with
Eq. (2), which yielded an IC50 value of 6.5 mM (W 1.4 mM) with a Hill coefficient of 1.0 (W 0.2). Each drug concentration was
applied to a minimum of five cells.
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IHERG.
3.2. Voltage dependence of IHERG blockade by doxepin
Voltage dependence of IHERG blockade by doxepin was
determined by the application, in control and doxepin-
containing solutions, of a series of 2 s duration depolarizing
commands to a range of test potentials up to +40 mV [32].
Successive command pulses were applied at 20 s intervals.
Representative control currents at selected command voltages
are shown in Fig. 3Ai; currents from the same cell following
equilibration in 10 mM doxepin are shown in Fig. 3Aii (upper
traces; lower traces in each panel show corresponding voltage
commands). At all test potentials, IHERG was inhibited by
doxepin. For each of five similar experiments, fractional
inhibition of IHERG tails following each voltage command was
calculated using Eq. (1); the mean  S.E.M. fractional block of
IHERG tails is plotted against command voltage in Fig. 3B. Also
shown in Fig. 3B are voltage-dependent activation relations for
IHERG in control solution and in the presence of doxepin (see
Section 2). The derived mean V0.5 and k values were: controlV0.5 = 21.0  3.1; doxepin V0.5 = 24.0  2.2, p > 0.1; control
k = 5.9  0.2; doxepin k = 7.5  1.7, p > 0.3, with the IHERG
activation relations in control and doxepin closely overlying
one another (Fig. 3B). Fractional block of IHERG showed no
statistically significant dependence on voltage over the range
from 40 to + 40 mV (p > 0.2; Anova).
The voltage dependence of IHERG availability/inactivation
was assessed using a 3-step protocol similar to those used in
previous IHERG investigations from our laboratory ([32,35], and
shown schematically as an inset to Fig. 3C). Mean data from
five experiments were corrected for deactivation [35] and the
resulting values were plotted to give availability plots in the
absence and presence of doxepin (Fig. 3C); the data-sets were
fitted with Eq. (4) (see Section 2). In control and doxepin the
inactivation V0.5 values were, respectively, 37.9  2.4 and
43.5  4.1 mV (ns, paired t-test), with corresponding k values
of 16.2  2.4 and 17.3  8.8 mV (ns, paired t-test). Thus,
doxepin did not alter the voltage-dependence of IHERG
inactivation. Although there was a trend towards an accel-
eration in the time-course of IHERG inactivation, this did not
attain statistical significance (inactivation time–constant of
3.3  1.2 ms in control versus 1.4  0.6 ms in doxepin, p > 0.1;
Fig. 2 – Doxepin inhibition of IHERG during action potential
(AP) voltage clamp and of native IKr tails. (A) The upper
traces show (leak corrected) representative currents of
heterologously expressed IHERG in the absence and
presence of 10 mM doxepin elicited by an AP clamp
protocol (lower trace; voltage command applied at 4 s
intervals). (B) Schematic representation of protocol used to
assess blockade of native IKr tails by doxepin. (C)
Representative tail currents from a rabbit ventricular
myocyte upon repolarization from +20 to S40 mV in the
absence (left panel) and in the presence of 100 mM doxepin
(right panel). Upper traces show current records and lower
traces show corresponding portion of the voltage protocol.
The horizontal dashed line is drawn at the level of the
current at S40 mV at the end of the initial (100 ms) step to
S40 mV, against which peak IKr amplitude on
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current elicited during the third step of the protocol, following
a brief hyperpolarizing step to 80 mV).
3.3. Time dependence of IHERG inhibition by doxepin
Gating-dependence of IHERG inhibition by doxepin was
investigated further by the use of two protocols to examine
the time-dependence of development of IHERG blockade. The
first protocol used a sustained (10 s) depolarizing step to 0 mV
from a holding potential of 80 mV (shown in Fig. 4A). This
protocol was applied first in the absence of doxepin to elicit
control IHERG. It was then discontinued whilst cells were
equilibrated in 10 mM doxepin (for 7 min), after which it was
re-applied. The first current trace recorded on resumption of
stimulation was used to determine development of fractional
blockade throughout the applied depolarization. Fig. 4A shows
representative traces in control and doxepin; these traces
diverged rapidly following depolarization, suggesting that
IHERG blockade developed rapidly with time. Fig. 4B shows plots
of mean  S.E.M. fractional block of IHERG at various time
intervals throughout the applied depolarization (main panel;
n = 8) and on an expanded time-scale to show development of
blockade over the first 0.5 s (inset). These plots show clearly
that IHERG blockade developed rapidly on depolarization, with
little change in blockade after 200–300 ms following the onset
of the voltage-command. The time-course of development of
blockade was well-described by a mono-exponential fit to the
data, with a rate constant (K) for the fit of 16.33 s1 (equivalent
to a time-constant (1/K) of 61 ms).
Although the protocol used in Fig. 4 is well suited for
examining the development of IHERG inhibition over a period of
seconds following membrane depolarization, it is less well
suited for accurate assessment of blockade of IHERG immedi-
ately following membrane depolarization than are protocols
based on tail current measurements [29,32]. Therefore, a
second protocol was also used [29]. Membrane potential was
held at –100 mV and, from this, 10 and 200 ms duration
depolarizations to +40 mV were applied, each followed by a
period at 40 mV to monitor IHERG tails [29]. Fig. 5A shows
representative currents from the same cell activated by 10 ms
(Fig. 5Ai) and 200 ms (Fig. 5Aii) commands in the absence and
presence of doxepin. Some IHERG tail inhibition was evident
following the 10 ms duration command, with further blockade
evident after the 200 ms command. Fig. 5B shows mean
fractional block of IHERG tails for five similar experiments.
Whilst blockade for 200 ms commands was significantly
greater than that for 10 ms commands (p < 0.02), the
occurrence of some blockade with only a very brief duration
depolarizing command is concordant with either a very
rapidly developing gating-dependent blockade on depolariza-
tion or with a contribution of closed-channel block to the
overall effect of doxepin [25,29,36].repolarization from +20 to +40 mV was measured. (D)
Mean fractional tail current block produced by three
different concentrations of doxepin fitted with Eq. (2),
which yielded an IC50 value of 4.4 (W 0.6 mM) with a Hill
coefficient of 0.7 (W 0.1). Each drug concentration was
applied to a minimum of twelve cells.
Fig. 3 – Voltage dependence of IHERG inhibition by doxepin. (A) Representative currents (upper traces) at selected voltages in:
(Ai) the absence and (Aii) presence of 10 mM doxepin, elicited by the voltage-protocol shown in the lower traces (only some
steps shown, for purposes of clarity of display). (B) Mean fractional block (n = 5) of peak IHERG tails produced by 10 mM
doxepin, between test potentials of S40 and +40 mV. Superimposed are the continuous plots of activation curves for IHERG
in the absence (dashed line) and presence (continuous line) of doxepin, calculated as described in Section 2. The mean
activation V0.5 and k values obtained from IHERG tail-voltage relations using Eq. (3) are given in Section 3. (C) Voltage-
dependence of IHERG availability/inactivation (protocol shown in inset). The mean (n = 5) normalised data (I/Imax) were
plotted against the test potential and fitted with Eq. (4). The derived half-maximal inactivation values were: control
V0.5 =S37.9W 2.4 mV and doxepin V0.5 =S 43.5W 4.1 mV in the absence (filled squares, dashed line) and presence
(filled triangles, continuous line) of 10 mM doxepin, respectively (ns paired t-test p = 0.79), with corresponding k values of
S16.2W 2.4 and S17.3W 8.8 mV (ns paired t-test p = 0.59).
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inhibition by doxepin
In order to investigate further the gating-dependence of IHERG
blockade by doxepin, experiments were performed using two
inactivation-attenuating HERG mutants: S631A and N588K.
Residue S631 is located towards the outer mouth of the HERG
channel pore, and the S631A (serine! alanine) mutation has
been reported to shift IHERG inactivation by +100 mV [26].
Residue N588 is located in the external S5-Pore linker of the
channel, and the N588K (asparagine ! lysine) mutation,
which is responsible for one form of the recently identified
genetic short QT syndrome [27], has been reported to shift
IHERG inactivation by +60 to +100 mV [35,37]. The effect of
each mutation on the potency of IHERG blockade by doxepin
was determined using the same protocol as was used toestablish concentration-dependence of WT IHERG blockade
(Fig. 1). Fig. 6Ai shows representative currents in control and
10 mM doxepin for WT–HERG, whilst Fig. 6Aii and Aiii show
similar records for S631A–HERG and N588K–HERG, respec-
tively. In contrast to WT–HERG, for both S631A–HERG and
N588K–HERG the IHERG tail magnitude was substantially
smaller than the maximal current during the voltage-
command (Fig. 6Aii and Aiii, respectively) reflecting the
greatly attenuated IHERG inactivation of these HERG mutants
[26,35,37]. Both mutant channels retained the ability to be
inhibited by doxepin. Exponential fits to currents activated on
depolarization to +20 mV for both mutants showed similar
time-courses of current activation in control solution and
following equilibration with 10 mM doxepin (S631A control:
60.6  5.5 ms; doxepin: 64.5  8.0 ms, p > 0.5; N588K control:
49.8  6.2; doxepin: 41.7  9.9 ms, p > 0.5; n = 5 for both). Three
Fig. 4 – Time-dependence of development of IHERG
inhibition during a sustained depolarization. (A) Lower
trace shows voltage-protocol (10 s depolarizing step from
S80 to 0 mV) used to elicit IHERG in the absence of doxepin
and following a 7-min exposure to 10 mM doxepin in the
absence of pulsing. (B) Mean fractional block of IHERG (n = 8)
produced by 10 mM doxepin during the 10-s depolarizing
step to 0 mV, following 7-min of drug application in the
absence of pulsing. Inset shows, on an expanded time-
scale, the development of blockade over the first 500 ms of
the protocol. Monoexponential fitting of the fractional
block time relationship yielded a rate constant (K) for the
fit of 16.33W 0.73 sS1 (equivalent to a time-constant (1/K)
of 61 ms).
Fig. 5 – IHERG inhibition by doxepin with brief-duration
voltage-commands. (A) For each of (Ai) and (Aii), the upper
traces show IHERG elicited by the voltage protocol shown in
the lower trace: (Ai) shows representative traces of
currents elicited by a 10-ms duration voltage command
from S100 to +40 mV in the absence and presence of
10 mM doxepin; (Aii) shows data from the same cell with a
200 ms duration command. (B) Plot of mean (WS.E.M.)
fractional block of IHERG tails following the 2 different
duration commands (n = 5; p < 0.02).
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obtain concentration-response data. Fig. 6B shows concentra-
tion-response relations (determined using Eq. (2)) for IHERG tail
inhibition for both S631A–HERG and N588K–HERG, with
corresponding data for WT–HERG plotted for comparison.
Although the S631A and N588K mutations produced small and
modest increases, respectively, in the IC50 derived from the fits
to the concentration-response relations (from 6.6 mM for WT
to 8.6 mM for S631A–HERG and 12.6 mM for N588K–HERG), these
differences did not attain statistical significance (p > 0.05;
Anova). These observations indicate the IHERG blockade by
doxepin was not highly sensitive to attenuation of HERG
channel inactivation.
3.5. Sensitivity of IHERG inhibition by doxepin to the S6
mutations Y652A and F656A
Two aromatic amino-acid residues, Y652 and F656, have been
shown to be important components of the drug-binding site
for a variety of HERG channel blockers [5,9,38]. Accordingly, we
investigated whether or not doxepin inhibition of IHERG was
sensitive to mutation of either residue, adopting a similar
approach and protocols to those used in other recent IHERGpharmacology studies [29,32,39–41]. Fig. 7 shows the effects on
doxepin inhibition of IHERG of the mutation Y652A (tyrosi-
ne ! alanine). The experimental voltage protocol used
(Fig. 7Aiii) was identical to that used for WT IHERG in Fig. 1
Fig. 6 – (A) Effect of inactivation mutants on IHERG inhibition
by doxepin. (Ai) Representative WT-HERG. (Aii) S631A-
HERG and (Aiii) N588K-HERG currents in the absence
(control, left hand traces) and presence of 10 mM doxepin
(right hand traces). The voltage protocol is shown as an
inset. (B). Mean fraction block of IHERG by 1, 10 and 100 mM
doxepin (each drug concentration was applied to at least
five cells; data for WT IHERG replotted from Fig. 1) fitted
with Eq. (2). The derived IC50 values for WT IHERG, S631A–
HERG and N588K–HERG were, respectively, 6.6W 0.6,
8.6W 0.0 and 12.6W 2.7 mM (p > 0.05; Anova); Hill
coefficients for the fits toWT, S631A and N588K data were,
respectively, 1.1 W 0.1, 0.8W 0.0, and 0.7 W 0.l (p < 0.05
between WT and N588K).
Fig. 7 – (A) Effect of the Y652A mutation on IHERG inhibition
by doxepin. (Ai) Representative WT-HERG and (Aii) Y652A-
HERG currents in the absence and (Aiii) the presence of
10 mM doxepin, elicited by voltage protocol. Inset in (Aii)
shows expanded tail-currents to highlight attenuation of
blockade for the Y652A mutant.(B) Concentration-
response relations for inhibition of IHERG by doxepin for
WT–HERG and Y652A–HERG, fitted with Eq. (2). Data for
WT IHERG are replotted from Fig. 1. For Y652A–HERG the
following concentrations were tested: 10 mM (n = 4), 30 mM
(n = 4); 100 mM (n = 12); 300 mM (n = 4) and 1 mM (n = 4). The
derived IC50 values for WT IHERG and Y652A IHERG were,
respectively, 6.5 W 1.4 and 27.8W 8.8 mM (p < 0.05); Hill
coefficients for the fits to WT IHERG and Y652A IHERG of
1.0 W 0.2 and 0.9 W 0.3 (p > 0.05).
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Representative traces showing the effect of 10 mM doxepin on
WT IHERG and Y652A IHERG are shown in Fig. 7Ai and Aii. WT
IHERG was inhibited substantially by this doxepin concentra-
tion (Fig. 7Ai). In contrast, inhibition of Y652A IHERG was
noticeably reduced (Fig. 7Aii; 28  3% peak tail current
inhibition compared to 62  4% for WT IHERG; p < 0.001). Four
other doxepin concentrations (30, 100, 300mM and 1 mM) were
also tested in order to construct a concentration response
relation for inhibition of Y652A IHERG tails (Fig. 7B). A fit to thedata with Eq. (2) (dashed line) yielded an IC50 for inhibition of
Y652A IHERG of 27.8  8.8 mM (with a Hill coefficient of 0.9  0.3),
which represented a modest, though significant (p < 0.05),
4.2 fold increase in IC50 over that for WT IHERG.
Fig. 8 – (A) Effect of the F656A mutation on IHERG inhibition
by doxepin. (Ai) Representative WT–HERG and (Aii) F656A-
HERG currents in the absence and presence of 100 mM
doxepin, elicited by voltage protocol (Aiii) on an expanded
time-scale (full protocol shown as an inset). (B) Bar chart
showing the mean fractional block levels produced for
WT–HERG and F656A–HERG tails measured at S120 mV
after addition of 100, 500 mM or 1 mM doxepin (n = 5 for
each). The F656A mutation significantly attenuated the
level of blockade produced by both 100 mM doxepin
(p < 0.01) and 500 mM doxepin (p < < 0.001), but not that by
1 mM doxepin (p > 0.05).
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the protocol shown in the inset of Fig. 8Aiii and inward tails
were measured at 120 mV [25,28,29]. Initial experiments
employed a doxepin concentration of 100 mM (shown in Fig. 1
to produce extensive inhibition of WT IHERG with a standard
[K+]e). Representative traces showing effects of this concen-
tration on WT and F656A IHERG are shown in Fig. 8Ai and Aii.
The F656A mutation produced a modest attenuation of IHERG
inhibition by this concentration of doxepin. However, as
observed previously for some other drugs (e.g. [28]), the extent
of inhibition of WT IHERG by 100 mM doxepin under conditions
of high [K+]e (see Section 2) was significantly smaller (56  5%)
than that observed with the same concentration in the
experiments with a standard [K+]e in Fig. 1 (93  4%;
p < 0.001). Therefore, the effects of two further concentrations
of doxepin (500 mM and 1 mM) were also examined. Fig. 8B
shows bar-chart plots of the mean levels of inhibition of WT
and F656A IHERG by the three doxepin concentrations. These
concentrations resulted in progressive increases in the level of
blockade of WT IHERG. In contrast, although Anova comparisonof the data with the three drug concentrations confirmed that
doxepin inhibition of F656A IHERG was concentration-depen-
dent (p < 0.001), the observed concentration-dependence was
unusual: there was no statistically significant difference
between the observed level of blockade of F656A IHERG between
100 and 500 mM, whilst at 1 mM the observed level of inhibition
of F656A IHERG was markedly increased (p < 0.001 compared to
each of 100 and 500 mM, Bonferroni post-test) and approached
that of WT IHERG. Taken together, the data with the three
doxepin concentrations suggest that the F656A mutation
exerted some influence on the ability of doxepin to inhibit
IHERG, though the F656A data did not appear to follow a
conventional monotonic concentration dependence.4. Discussion
Despite a strong association between TCA use and QT interval
lengthening [42], and although doxepin itself has been linked
with both QT interval prolongation and TdP [18–20], the effects
of this drug on HERG K+ channels have not hitherto been
reported. Moreover, whilst IHERG blockade has been investi-
gated previously for the TCAs imipramine and amitriptyline
[21–23], to our best knowledge the present study is the first in
which molecular determinants of IHERG inhibition have been
investigated for any member of the TCA family.
4.1. Characteristics of IHERG blockade by doxepin
Previously, imipramine has been reported to inhibit IHERG
recorded in experiments using a mammalian expression
system with an IC50 of 3.4 mM [23] whilst an IC50 of 10 mM
was reported for amitriptyline [21]. A different study of
amitriptyline, using the Xenopus oocyte expression system,
reported IC50’s of 3.3–4.8 mM (depending on [K+]e) [22]. Thus,
the potency of doxepin as an IHERG inhibitor found here (IC50 of
6.5 mM) is broadly comparable to that seen previously for these
other two TCAs. However, in terms of the characteristics of
observed IHERG blockade, doxepin appears to be closer to
imipramine than to amitriptyline: amitriptyline block of IHERG
has been reported to show significant voltage-dependence [22]
whereas imipramine showed only weak voltage-dependence
[23]. Moreover, no significant effects of doxepin on the voltage-
dependence of activation or inactivation were seen in this
study. Unfortunately, comparative data for the TCAs imipra-
mine and amitriptyline are lacking [21–23] and, therefore, a
direct comparison between doxepin and these agents cannot
be made in this regard. However, the atypical tetracyclic
antidepressant maprotiline has recently been reported to
show no alteration to the voltage-dependence of activation
and inactivation [43], though another study contradicted this
with regard to activation [44]. The lack of a significant leftward
shift in the voltage-dependence of inactivation with doxepin
in our study suggests that this agent does not act to stabilise
IHERG inactivation, and the time-course of WT IHERG inactiva-
tion was not significantly accelerated by the drug. Moreover,
the results with inactivation-attenuating mutations to two
residues from distinct parts of the channel (S631A: outer
mouth of the channel pore; N588K: in the S5-Pore linker)
provide evidence that IHERG inactivation does not play an
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further supported by unaltered levels of WT IHERG blockade
with progressive depolarization over voltages at which IHERG
was maximally activated, but over which inactivation
increased (Fig. 3C and D). Doxepin is quite distinct in this
regard from a number of other drugs, including the archetypal
high affinity HERG blocking methanesulphonanilide drugs E-
4031 and dofetilide, for which IHERG inactivation exerts a
strong influence on blocking potency – either as a direct
consequence of inactivation-state dependent block, or due to
conformational changes during inactivation facilitating
optimal orientation of S6 helical residues to which drugs
bind [10,45–48].
Blockade of IHERG by imipramine has been reported to
develop rapidly during a sustained depolarization, with a
component of inhibition visible even for comparatively brief
depolarizing voltage commands [23]. These features of
imipramine’s action correspond well with those seen for
doxepin in the present study. They are also similar to those
reported for the serotonin-selective reuptake inhibitors (SSRIs)
fluvoxamine and citalopram [25,49], but differ significantly
from the methanesulphonanilides, for which little blockade is
observed immediately upon depolarization, with blockade
then increasing progressively during the maintained depolar-
ization [24,49,50]. The lack of a strong dependence of HERG
channel blockade by doxepin on IHERG inactivation suggests
that gating-dependent blockade by this drug is likely to arise
predominantly to activated/open channels. Accordingly, the
observed time-dependence of IHERG inhibition by doxepin in
this study is consistent with either a mixed state-dependence
of blockade (with components of both closed and open
channel blockade) or with the presence of a very rapidly
developing component of activation-dependent inhibition
immediately on depolarization.
For the majority of drugs that have been studied, one or
both of the Y652 and F656 aromatic amino acid residues in the
S6 helices of the HERG channel comprise key elements of the
drug binding site [5,9,38,51]. For example, the Y652A and
F656A mutations increased the IC50 for HERG blockade by the
methanesulphonanilide MK-499 by 94-fold and 650-fold,
respectively, and that for terfenadine by 100-fold [8]. In
comparison, the 4-fold increase in IC50 for doxepin
produced by the Y652A mutation in this study, is rather
modest, suggesting that this residue is less influential for
binding of doxepin than for either of these high affinity
blockers. The unusual concentration dependence seen with
the F656A mutation indicated that at a high doxepin
concentration of 1 mM IHERG blockade was little affected by
mutation of this residue, whilst at concentrations of 100 and
500 mM significant attenuation of blockade occurred with no
significant increase in block at 500 mM compared to 100 mM. It
was not possible to obtain an adequate fit of these data with
Eq. (2). A cautious interpretation of the lack of a conventional
concentration-dependence of F656A–HERG inhibition by
doxepin is that blockade may depend partly, but incomple-
tely, on this residue. Neither the Y652A nor F656A mutations
attenuated blockade by doxepin concentrations producing
very high levels (>90%) of blockade of WT IHERG, suggesting
that neither residue is absolutely obligatory for doxepin
binding to HERG channels to occur. Whilst unusual, this is notunprecedented; IHERG block by both the SSRI fluvoxamine and
the antiarrhythmic agent dronedarone has been reported to
be only partially attenuated by the Y652A and F656A
mutations [25,28]. Comparative data for other TCAs are
lacking, though recently these residues have been implicated
in IHERG inhibition by the tetracyclic drug maprotiline [43,44];
one of these two studies obtained IC50 values for the Y652A
and F656T mutants, with respective (modest) 3-fold and 7-
fold increases in IC50 [43]. Whilst obligatory molecular
determinants of doxepin-binding to HERG remain to be
found, the fact that IHERG inhibition by doxepin developed
progressively over several minutes following rapid external
solution exchange is consistent with the drug crossing the cell
membrane to reach its site of action. The reduced IHERG
inhibition by doxepin of WT IHERG in the presence of raised
[K+]e may also be of significance. Since IHERG inhibition by
doxepin appears not to be critically dependent on channel
inactivation, decreased blockade with high [K+]e is unlikely to
result from any effect of [K+]e on IHERG inactivation. Rather,
reduced inhibition in high [K+]e may be accounted for by an
interference with drug-binding due to an electrostatic
repulsion or ‘‘knock-off’’ process [28,52], consistent with
drug binding to the channel at a site close to the ion
conduction pathway. It remains to be determined whether
this site would need to reside within the channel pore.
However, in a limited series of experiments using the D540K
mutant [53], we did not find evidence that doxepin can readily
unbind on hyperpolarization-induced channel opening (data
not shown); though not all drugs that bind within the pore
exhibit marked ‘untrapping’ [54]. Nevertheless, given the
presence of a significant component of IHERG blockade with
brief depolarization and incomplete attenuation of inhibition
by the Y652A and F656A mutations, we cannot exclude the
possibilities that a proportion of the observed blockade with
doxepin involves binding outside of the channel pore, or
binding to closed HERG channels.
4.2. Clinical significance of IHERG blockade by doxepin
TCAs are associated with QTc interval lengthening in clinical
use [42], and IHERG inhibition by doxepin observed in the
present study is consistent both with documented cases of QT
interval prolongation and TdP with doxepin [18–20] and with
QT interval increases seen in anaesthetised guinea-pigs
receiving doxepin infusion [15]. Our study was conducted at
a physiologically relevant temperature and the extent of IHERG
blockade by doxepin was similar between ventricular action
potential and conventional voltage step protocols. A lack of
relief of IHERG blockade on membrane hyperpolarization for the
D540K mutant (mentioned in Section 4.1, above) is suggestive
of relatively poor drug unbinding at negative voltages in the
maintained presence of drug, whilst the data shown in Fig. 5
indicate that at 10 mM (the same concentration as used for the
AP clamp experiment in Fig. 2) doxepin was able to bind and
inhibit IHERG rapidly on membrane depolarization to a positive
voltage. These factors may combine to account for the similar
levels of IHERG inhibition by doxepin observed with step and AP
clamp protocols. Although we did not co-express HERG with
MiRP1, a putative b subunit suggested to be necessary to
recapitulate native IKr [55], it has recently been suggested that
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conduction system [51] and, additionally, the pharmacological
sensitivity of HERG channels expressed in mammalian cells
without MiRP1 co-expression has been found to be similar to
that of native IKr [56]. This notion is reinforced by the close
concordance of inhibitory potency of doxepin on IHERG and
native IKr in our experiments (IC50 values of 6.5 and 4.4 mM,
respectively). A question therefore arises as to the relationship
between the potency of IHERG/IKr blockade seen in this study
and plasma concentrations of doxepin in patients. As a class,
the TCAs are lipophilic and are known to become concentrated
in some tissues, including the myocardium [57]. In the case of
doxepin, one experimental study has reported doxepin
concentration in cardiac muscle to be 41-fold higher than
plasma levels [58]. This makes it difficult to extrapolate with
accuracy from known plasma concentrations to likely levels of
IHERG/IKr blockade by doxepin in vivo. The therapeutic plasma
level of doxepin is thought to be between 50 and 250 ng/ml
(0.16–0.8 mM), although a wide variety of recommendations
from university psychiatric departments and laboratories (up
to 1000 ng/ml; 3.2 mM) have been reported [59]. Whilst IHERG (or
IKr) blockade at the lower end of this range might be
anticipated to be modest, inhibition at higher concentrations
would be significant and, taking into account also potential
cardiac accumulation, the observed potency of IHERG inhibition
by doxepin in this study is likely to be clinically relevant,
particularly in overdose. Such an effect may be exacerbated in
individuals exhibiting pre-existing QT interval prolongation
(congenital or acquired), electrolyte abnormalities or with
impaired drug metabolism. Thus, as for other IHERG blocking
medications, caution is warranted in its use in patients with
pre-existing QT interval prolongation or with risk factors likely
to exacerbate the effects of IHERG blocking medications.
The findings of this study have further clinical relevance in
a second, perhaps less expected, respect. The attenuated-
inactivation N588K–HERG mutant used in this study has been
shown recently to underlie the SQT1 familial form of the
recently identified genetic ‘Short QT syndrome’, which carries
a risk of cardiac arrhythmia and sudden death [27,60].
Pharmacological approaches to correcting the QT-interval of
SQT1 patients are currently very limited. These patients are
comparatively insensitive to Class III IKr/HERG blocking drugs
[27,61] and the N588K–HERG blocking potencies of the IKr/
HERG blockers E-4031and D-sotalol are reduced 12–20-fold
compared to their effects on WT–HERG [62,63], presumably
due to a role (direct or otherwise) of channel inactivation in
facilitating drug binding to the HERG channel. To date, only the
Class Ia antiarrhythmic drug quinidine has been found both to
inhibit N588K–HERG effectively and to correct the QT interval
in such patients [27,62,63]; however, very recently, another
Class Ia antiarrhythmic, disopyramide, has been shown to be
effective against N588K–HERG in vitro [63]. The present study
identifies doxepin as both an IHERG-blocker for which channel
inactivation does not play a major role in drug binding and as
an additional drug that is an effective inhibitor of N588K–
HERG. Whilst the sedative effects of doxepin may make it
unsuitable as a corrective treatment for SQT1 patients, our
findings prompt the question as to whether chemical
structures related to doxepin might feasibly offer viable IHERG
blocking agents in SQT1.Acknowledgements
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